Man Group PLC Cardiff Oncology, Inc. Transaction History

Man Group PLC

  • $36 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$2.22 - $5.89 $131,865 - $349,860
-59,399 Reduced 52.68%
53,357 $118,000
Q1 2024

May 15, 2024
BUY
$1.46 - $5.91 $164,623 - $666,387
112,756 New
112,756 $602,000
Q3 2023

Nov 14, 2023
BUY
$1.38 - $2.18 $97,521 - $154,056
70,668 New
70,668 $98,000

Others Institutions Holding CRDF

# of Institutions
90
Shares Held
12.3M
Call Options Held
813K
Put Options Held
91.1K
View Full List

About Cardiff Oncology, Inc.

CRDF Quotes by TradingView
  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $170M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email